Intangibles

12 Months Ended

Jun. 30, 2023

Note 1

. Intangibles

Non-current

assets


	Consolidated
				2022
	2023 A$’000			restated A$’000

Licensing agreement - Paxalisib		16,408			16,408
Less: Accumulated amortisation		(7,251	)		(6,166	)

		9,157			10,242

Licensing agreement - EVT-801		9,813			9,813
Less: Accumulated amortisation		(1,701	)		(916	)

		8,112			8,897

		17,269			19,139

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:


	EVT801 licensing agreement A$’000			Paxalisib licensing agreement A$’000			Total A$’000

Balance at 1 July 2021 as restated		9,682			11,326			21,008
Amortisation expense		(785	)		(1,084	)		(1,869	)

Balance at 30 June 2022 restated		8,897			10,242			19,139

Amortisation expense		(785	)		(1,085	)		(1,870	)

Balance at 30 June 2023		8,112			9,157			17,269